FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+53.73%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$165M
AUM Growth
–
Cap. Flow
+$165M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
92.81%
Holding
15
New
15
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
$24.3M |
| 2 |
Insmed
INSM
|
$23.6M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$22.1M |
| 4 |
AMRN
Amarin Corp
AMRN
|
$18M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$12.6M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 98.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
| $24.3M | 14.75% | +466,875 | New | +$24.3M |
|
|
2
Insmed
INSM
$28.8B
| $23.6M | 14.31% | +988,999 | New | +$23.6M |
|
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $22.1M | 13.37% | +515,788 | New | +$22.1M |
|
|
AMRN
4
Amarin Corp
AMRN
$311M
| $18M | 10.94% | +841,714 | New | +$18M |
|
|
5
Iovance Biotherapeutics
IOVA
$807M
| $12.6M | 7.62% | +453,890 | New | +$12.6M |
|
6
argenx
ARGX
$43.6B
| $12.5M | 7.6% | +78,138 | New | +$12.5M |
|
|
ALLK
7
DELISTED
Allakos
ALLK
| $12.3M | 7.44% | +128,662 | New | +$12.3M |
|
8
Enanta Pharmaceuticals
ENTA
$180M
| $10M | 6.06% | +161,949 | New | +$10M |
|
9
Neurogene
NGNE
$264M
| $9.98M | 6.05% | +810,073 | New | +$9.98M |
|
10
Karyopharm Therapeutics
KPTI
$61.7M
| $7.7M | 4.67% | +401,609 | New | +$7.7M |
|
11
Ascendis Pharma
ASND
$11.8B
| $4.13M | 2.5% | +29,676 | New | +$4.13M |
|
|
ACHN
12
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $3.77M | 2.28% | +624,956 | New | +$3.77M |
|
|
XENT
13
DELISTED
Intersect ENT, Inc
XENT
| $2M | 1.21% | +80,238 | New | +$2M |
|
14
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.83M | 1.11% | +165,318 | New | +$1.83M |
|
15
Protara Therapeutics
TARA
$120M
| $140K | 0.08% | +341,743 | New | +$140K |
|